RHHBY : Summary for ROCHE HLDGS AG SPN ADR EACH REP - Yahoo Finance

U.S. Markets open in 8 hrs 56 mins

Roche Holding AG (RHHBY)


Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
30.53+0.02 (+0.07%)
At close: 3:59PM EST
People also watch
NVSSNYNSRGYAZNBAYRY
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close30.51
Open30.39
Bid0.00 x
Ask0.00 x
Day's Range30.29 - 30.55
52 Week Range25.25 - 33.77
Volume570,121
Avg. Volume1,363,886
Market Cap207.03B
Beta0.64
PE Ratio (TTM)21.75
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield1.02 (3.34%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Investopedia12 hours ago

    Roche Sues Amgen Over Avastin Biosimilar Drug

    Roche filed suit to fend off competition from Amgen’s biosimilar for its bestselling drug Avastin.

  • 3 Stocks to Invest in Big Pharma
    Motley Fool15 hours ago

    3 Stocks to Invest in Big Pharma

    These drug kingpins are raking in the dough, which could lead to handsome returns for investors.

  • Reuters3 days ago

    Roche says Phase II trial supports twin treatment for kidney cancer

    Swiss pharmaceuticals company Roche said on Saturday that a combination of its immunotherapy drug Tecentriq and its blockbuster cancer drug Avastin had shown encouraging results in a Phase II trial in treating a type of kidney cancer. The study found that the combination had a "manageable safety profile" when used for locally advanced or metastatic renal cell carcinoma (mRCC). The tests showed promising effectiveness compared with the standard treatment for mRCC, sunitinib, which is sold by Pfizer under the brand name Sutent.